Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Y-Mabs Therapeutics Inc (NQ: YMAB )

12.95 +0.39 (+3.11%)
Streaming Delayed Price Updated: 2:07 PM EDT, May 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Y-Mabs Therapeutics Inc

< Previous 1 2 3 4 Next >
YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q1 2024
YMAB stock results show that Y-mAbs Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Cracking The Code: Understanding Analyst Reviews For Y-mAbs Therapeutics
Via Benzinga
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results. 
Via Benzinga
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
Earnings Outlook For Y-mAbs Therapeutics
Via Benzinga
Earnings Preview For Y-mAbs Therapeutics
Via Benzinga
4 Analysts Have This to Say About Y-mAbs Therapeutics
Via Benzinga
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why NetApp Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Shares of NetApp, Inc. (NASDAQ: NTAP) shares rose sharply in today’s pre-market trading after the company reported better-than-expected third-quarter financial results and issued guidance. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Analyst Expectations for Y-mAbs Therapeutics's Future
Via Benzinga
Where Y-mAbs Therapeutics Stands With Analysts
Via Benzinga
B of A Securities Maintains Neutral Rating for Y-mAbs Therapeutics: Here's What You Need To Know
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Beam Therapeutics Stock Shows Healthy Relative Strength Improvement
In a welcome move, Beam Therapeutics stock saw its Relative Strength (RS) Rating rise from 67 to 76 on Friday. 
Via Investor's Business Daily
Micro Marvel - Y-Mabs Therapeutics
Wall Street projected revenue will grow 26.00% this year and another 18.80% next year. Earnings are estimated to increase 68.90% this year but decrease 8.80% next year. 
Via Talk Markets
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Preview: Y-mAbs Therapeutics's Earnings
Via Benzinga
Earnings Scheduled For November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. 
Via Benzinga
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
Via Benzinga
Analyst Upgrades Y-mAbs On Bullish Danyelza Sales Outlook, Improved Visibility
Wedbush has upgraded Y-mAbs Therapeutics Inc (NASDAQ: YMAB)to Outperform from Neutral, with a  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023
Via Benzinga
Earnings Scheduled For May 8, 2023
Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million. 
Via Benzinga
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 3, 2023
Via Benzinga
Crude Oil Rises 1.5%; Checkpoint Therapeutics Shares Slide
U.S. stocks traded higher toward the end of trading, with the Dow Jones jumping more than 200 points on Friday. The Dow traded up 0.72% to 33,095.32 while the NASDAQ rose 1.09% to 12,144.31. The S&P... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Quarterly Gain Still Eludes Dow Despite Triple-Digit Lead
The Dow Jones Industrial Average is boasting a triple-digit lead this afternoon, as investors unpack this morning's flood of inflation data. 
Via Talk Markets
Why Y-mAbs Therapeutics Shares Are Trading Higher By 50%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) climbed 49.9% to $4.93 after the company posted a profit for the fourth quarter. 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.